{"source_content":"1证券研究报告作者：行业评级：上次评级：行业报告|请务必阅读正文之后的信息披露和免责申明医药生物强于大市强于大市维持2020年10月13日（评级）分析师潘海洋SAC执业证书编号：S1110517080006分析师郑薇SAC执业证书编号：S11105171100032020年Q3血制品批签发报告——整体批签发增长，单季度国产白蛋白占比提升行业专题研究摘要请务必阅读正文之后的信息披露和免责申明新冠疫情凸显行业重要地位，国外疫情持续带来较强白蛋白提价预期2019年底以来的新冠疫情，带来了对静丙等治疗性血液制品的大量需求，对恢复期血浆以及静丙、白蛋白等治疗性血制品的宣传，有利于教育医生和民众认识血制品；同时，在新冠这类重大公众卫生事件发生时，血制品及恢复性血浆起到了一定治疗作用，体现出血液制品的重要地位及资源稀缺属性，随着国外疫情持续，进口白蛋白企业采浆受限，进口白蛋白可能减少，加之疫情期间国内采浆量的减少，使得后续白蛋白供应可能下降，国产白蛋白有较强提价预期。2020Q1-Q3整体批签发增加，Q3国产白蛋白占比有所提升，特免类有所下降从2020Q1-Q3批签发量上来看，静丙受到疫情影响需求增加，批签发同比10%，其他产品同比也有较大增加，其中白蛋白同比增加16%，其中进口白蛋白同比约+26%，国产白蛋白同比约+1%，单季度国产占比由Q2的33%提升至44%；特免类整体批签发量较去年同期有所下降，其中狂免批签发量同比下降10%，破免批签发量同比下降16%，乙免批签发量同比下降2%；因子类，因子Ⅷ同比+43%，PCC同比+41%，纤原批签发小幅增加，同比+20%。建议关注浆量持续提升、产品齐全的血制品企业短期看，受到疫情影响血制品企业业绩增长有限，但从长期来看，血制品高壁垒，行业具有战略意义，供给端弹性有限，企业通过持续进行渠道建设、营销和学术推广，拉动终端纯销需求的增长。建议关注浆量有望持续提升、产品齐全、学术推广强、渠道能力优秀的血制品企业，继续推荐天坛生物、华兰生物、博雅生物，建议关注卫光生物、双林生物。风险提示：行业黑天鹅事件；新品种研发进展低于预期；政策变化风险；企业经营质量管理风险23代码名称2020-10-12评级2019A2020E2021E2022E2019A2020E2021E2022E600161.SH天坛生物41.09买入0.490.550.650.7783.8674.7163.2253.36002007.SZ华兰生物61.96买入0.700.881.071.2788.5170.4157.9148.79300294.SZ博雅生物42.80买入0.981.061.251.4843.6740.3834.2428.92重点标的推荐股票股票收盘价投资EPS(元)P/E请务必阅读正文之后的信息披露和免责申明摘要总览：2020年Q1-Q3批签发量整体增长，特免类有所下降资料来源：中检院及各所，天风证券研究所整理4表：2020年Q1-Q3血制品批签发量2020Q1-Q3血制品批签发整体同比表现稳健，从具体品种来看：➢白蛋白：2020Q1-Q3批签发约4477万件，同比大幅提升16%，其中进口白蛋白批签发约2857万件，同比+约26%，批签发占比64%，国产白蛋白批签发约1632万件，同比+约1%，批签发占比36%；➢免疫球蛋白：大品种：2020Q1-Q3共批签发静丙975.4万瓶，同比增长+10%，狂免近838.1万瓶，同比-10%，破免390.3万瓶，同比-16%；乙免：2020Q1-Q3批签发约56.1万瓶，同比-2%。➢因子类：因子Ⅷ2020Q1-Q3批签发约166.4万瓶，同比大幅+43%，PCC批签发约107.4万件，同比+41%，纤原批签发批签发81.7万件，同比+20%。标准规格，万件2020年2020Q1-Q32019Q1-Q3YoYQ1Q2Q3冻干静注人免疫球蛋白（pH4）15.68.011.535.117.5101%冻干静注乙型肝炎人免疫球蛋白（pH4）0.02.70.02.72.55%静注人免疫球蛋白（pH4）455.9258.9260.6975.4890.010%静注乙型肝炎人免疫球蛋白（pH4）0.71.40.72.81.760%狂犬病人免疫球蛋白247.1332.0259.1838.1935.5-10%破伤风人免疫球蛋白162.1143.185.1390.3465.7-16%人免疫球蛋白61.631.027.6120.257.2110%人凝血酶原复合物36.044.127.3107.476.141%人凝血因子Ⅷ61.040.764.7166.4116.743%人纤维蛋白原27.534.919.381.767.920%人血白蛋白1611.91548.71316.54477.23874.716%乙型肝炎人免疫球蛋白20.215.820.256.157.2-2%人血白蛋白：Q1-Q3批签发同比增加16%，国产占比由Q233%提升至Q344%5图：2013-2020Q1-Q3批签发变化图：国产和进口白蛋白占比变化资料来源：中检院及各所，天风证券研究所整理➢2020Q1-Q3批签发约4477万件，同比提升16%，其中进口白蛋白批签发约2845万件，同比+约26%，批签发占比64%，国产白蛋白批签发约1632万件，同比+约1%，批签发占比36%。➢2020Q1-Q3白蛋白批签发同比增加约602万瓶，其中进口白蛋白增加约591万件，占增加值约98%，国产白蛋白增加约11万件，占增加值约2%，进口/国产批签发比由2019年Q1-Q3的约58:42增加到近64:36，进口白蛋白仍旧占白蛋白批签发的大多数。➢单看2020Q3批签发约1316.5万件，环比-15.0%，其中国产576.1万件，环比+12.3%，占比44%，占比环比提升11个pp，进口740.4万件，环比-28.5%，占比56%，占比环比下降11个pp。0%10%20%30%40%50%60%70%80%90%100%国产企业进口企业0%5%10%15%20%25%0100020003000400050006000人血白蛋白增速万件6资料来源：中检院及各所，天风证券研究所整理➢国内上市企业中：天坛、泰邦、莱士和华兰在2020Q1-Q3白蛋白批签发份额最大，上海莱士增速最高为15%。国产血制品公司前四分别是：天坛生物（8.1%）、泰邦生物（6.0%）、上海莱士（5.0%）、华兰生物（4.2%）。➢从国内企业批签发占比来看，2020Q1-Q3占比在前四的分别为天坛生物（22.2%）、泰邦生物（16.6%）、上海莱士（13.9%）和华兰生物（11.5%），相比于2019Q1-Q3的占比分别+1.1、-1.8、+1.7、+0.03个PP。图：主要企业批签发量变化050100150200250300201720182019Q1Q2Q32020华兰生物万件050100150200250300201720182019Q1Q2Q32020上海莱士万件0100200300400500201720182019Q1Q2Q32020天坛生物万件0100200300400201720182019Q1Q2Q32020泰邦生物万件050100150200201720182019Q1Q2Q32020远大蜀阳万件020406080100201720182019Q1Q2Q32020博雅生物万件人血白蛋白：国产大份额公司占比维持相对稳定静注人免疫球蛋白：前三季度批签发同比提升10%7图：2013-2020Q1-Q3批签发变化图：2020Q1-Q3各企业批签发量资料来源：中检院及各所，天风证券研究所整理➢2020Q1-Q3批签发975.4万瓶，同比增幅+10%。单三季度批签发260.6万瓶，同比-38%，环比+1%。➢2020Q1-Q3共有12个企业有批签发（上市公司中合并母公司+控股子公司），其中批签发较多的企业有：天坛生物（占比25%）、上海莱士（占比16%）、泰邦生物（占比14%）、华兰生物（占比9%）、远大蜀阳（占比7%）。-10%-5%0%5%10%15%20%25%30%35%0200400600800100012001400静注人免疫球蛋白（pH4）增速博雅生物6%哈尔滨派斯菲科4%华兰生物9%绿十字（中国）1%南岳生物4%山西康宝4%上海莱士16%双林生物5%泰邦生物14%天坛生物25%卫光生物5%远大蜀阳7%8资料来源：中检院及各所，天风证券研究所整理➢2020Q1-Q3，天坛、莱士和泰邦静丙批签发份额最大，莱士、派斯菲科、博雅在批签发同比增速方面脱颖而出。批签发占比较大的公司有：天坛生物（244万，同比+7%）、上海莱士（157万，同比+65%）、泰邦生物（140万，同比-10%）、华兰生物（89万，同比-13%）、远大蜀阳（68万，同比-1%）、博雅生物（53万，同比+28%）、卫光生物（48万，同比+7%）。图：主要企业批签发量变化静注人免疫球蛋白：天坛、泰邦排名靠前，上海莱士、派斯菲科增速亮眼050100150200250300Q1Q2Q32017201820192020天坛生物万件020406080100120140160Q1Q2Q32017201820192020上海莱士万件050100150200Q1Q2Q32017201820192020泰邦生物万件050100150200Q1Q2Q32017201820192020华兰生物万件020406080100120Q1Q2Q32017201820192020远大蜀阳万件020406080Q1Q2Q32017201820192020博雅生物万件狂犬病人免疫球蛋白：前三季度批签发下降10%9资料来源：中检院及各所，天风证券研究所整理➢2020Q1-Q3狂免批签发近838万瓶，同比-10%，批签发小幅下降。单三季度批签发256万瓶，同比-42%，环比-22%。➢2020Q1-Q3狂免批签发份额排名靠前的厂家分别为泰邦生物（18%）、远大蜀阳（18%）、卫光生物（16%）、双林生物（11%）、上海莱士（9%）、天坛生物（8%）、华兰生物（8%），其中卫光和泰邦批签发分别同比增长43%、22%。图：2013-2020Q1-Q3批签发变化图：2020Q1-Q3各企业批签发量占比表：2017-2020Q1-Q3各企业批签发量万件-60%-40%-20%0%20%40%60%80%0200400600800100012001400狂犬病人免疫球蛋白增速博晖创新2%博雅生物7%华兰生物8%南岳生物4%上海莱士9%双林生物11%泰邦生物17%天坛生物8%卫光生物16%远大蜀阳18%标准规格2017201820192020万件Q1Q2Q3合计554.30828.561237.49247.07331.97259.09博晖创新26.3426.1511.524.24博雅生物9.3645.3465.5724.9812.1220.07华兰生物47.73150.58125.8617.2616.5430.62南岳生物43.5648.3459.5435.30上海莱士50.10140.47232.2216.8056.96双林生物135.3744.49143.4115.8731.1343.31泰邦生物106.30109.79179.1542.1280.4825.23天坛生物64.67111.8926.8127.8412.10卫光生物76.5745.29103.8350.3959.6726.06远大蜀阳85.31145.10189.8841.3264.6744.74破伤风人免疫球蛋白：批签发小幅下降，双林生物二季度显著增加10资料来源：中检院及各所，天风证券研究所整理图：2013-2020Q1-Q3批签发变化表：2017-2020Q1-Q3各企业批签发量➢2020Q1-Q3破免批签发390万瓶，同比-16%，同比小幅下降。单三季度批签发85万瓶，同比-61%，环比-41%。➢2020Q1-Q3批签发靠前的企业有泰邦生物、华兰生物、远大蜀阳、天坛生物，同比增速分别为-5%、+7%、-3%和-52%，批签发占比分别为27%、22%、15%和13%。图：2020Q1-Q3各企业批签发量占比-40%-20%0%20%40%60%80%100%0100200300400500600700破伤风人免疫球蛋白增速博晖创新1%华兰生物22%上海莱士12%双林生物9%泰邦生物27%天坛生物13%卫光生物1%远大蜀阳15%标准规格2017201820192020万件Q1Q2Q3总计450.57338.27606.13162.08143.1485.06博晖创新5.251.98华兰生物125.6186.93140.4550.305.4729.76南岳生物10.644.40上海莱士24.6240.6139.6223.8222.57双林生物80.3142.4342.326.5418.7410.51泰邦生物93.0863.82132.2646.8241.9816.13天坛生物67.3249.85138.8719.4623.717.80卫光生物31.985.3525.944.62远大蜀阳26.0338.6577.0415.1424.0720.86中原瑞德1.62乙型肝炎人免疫球蛋白：2020Q1-Q3批签发同比-2%11资料来源：中检院及各所，天风证券研究所整理图：2013-2020Q1-Q3批签发变化表：2017-2020Q1-Q3各企业批签发量图：2020Q1-Q3各企业批签发量占比➢2020Q1-Q3乙免批签发56万瓶，同比-2%。单三季度批签发20万瓶，同比+123%，环比+28%。➢乙免批签发量较小，与静注乙免、冻干静注乙免在一定程度上可互相代替，在季度上也呈现出多少交替的趋势。2020Q1-Q3批签发量由高到低的企业分别为华兰生物、远大蜀阳、天坛生物、泰邦生物、博雅生物和南岳生物，占比分别为34%、33%、15%、8%、7%和3%，卫光生物、双林生物和上海莱士无批签发。-40%-30%-20%-10%0%10%20%050100150200250乙型肝炎人免疫球蛋白增速标准规格2017201820192020万件Q1Q2Q3乙型肝炎人免疫球蛋白139.68157.23103.8420.1515.7520.21博雅生物3.67华兰生物39.9728.2312.796.964.008.27南岳生物4.3913.9512.961.83上海莱士35.6021.1825.19双林生物8.42泰邦生物15.2921.6612.514.25天坛生物17.5815.9527.358.46卫光生物12.0418.606.70远大蜀阳14.8029.236.335.2811.761.65博雅生物7%华兰生物34%南岳生物3%泰邦生物8%天坛生物15%远大蜀阳33%人凝血因子Ⅷ：整体批签发同比大幅+43%，莱士批签发提升明显12资料来源：中检院及各所，天风证券研究所整理图：2013-2020Q1-Q3批签发变化➢2020Q1-Q3人凝血因子Ⅷ批签发166万瓶，同比大幅+43%。单三季度批签发65万瓶，同比+37%，环比+59%。➢2020Q1-Q3因子Ⅷ批签发共有5家企业，其中上海莱士、绿十字（中国）批签发大幅增加，各企业批签发量分别为上海莱士53.7万件、华兰生物43.0万件、泰邦生物42.9万件、绿十字中国26.5万件和天坛生物3673件，分别占比32%、26%、26%、16%和0.2%。表：2019年-2020Q1-Q3各企业批签发量图：2020Q1-Q3各企业批签发量占比-10%0%10%20%30%40%50%050100150200人凝血因子Ⅷ增速华兰生物26%绿十字（中国）16%上海莱士32%泰邦生物26%天坛生物0.2%标准规格2017201820192020万件Q1Q2Q3人凝血因子Ⅷ129.19174.04170.9460.9840.7564.69华兰生物51.2164.3062.8619.3610.2313.38绿十字（中国）32.4742.1525.9911.741.6213.11上海莱士19.4124.2338.7619.3414.4519.96泰邦生物24.2340.2643.3310.1814.4518.24天坛生物0.37中国医药1.853.11人凝血酶原复合物：2020Q1-Q3同比大幅提升，泰邦、华兰表现亮眼13资料来源：中检院及各所，天风证券研究所整理图：2013-2020Q1-Q3批签发变化➢2020Q1-Q3人凝血酶原复合物批签发107.4万瓶，同比+41%。单三季度批签发27万瓶，同比-28%，环比-38%。➢2020Q1-Q3仅有3家企业有PCC批签发，其中泰邦生物65万件，同比+41%，华兰生物40万件，同比+41%，南岳生物2020Q3首次获批签发2万件，批签发占比分别60%、38%和2%。表：2017-2020Q1-Q3各企业批签发量图：2020Q1-Q3各企业批签发量占比-20%-10%0%10%20%30%40%50%020406080100120人凝血酶原复合物增速华兰生物38%南岳生物2%泰邦生物60%标准规格2017201820192020万件Q1Q2Q3合计106.79101.7898.3536.0144.1227.29华兰生物65.3345.3943.0018.2912.389.56南岳生物2.45泰邦生物33.9941.3353.8617.7231.7415.28天坛生物0.03中国医药7.4415.061.49人纤维蛋白原：莱士批签发大幅增加，贡献主要增量14资料来源：中检院及各所，天风证券研究所整理图：2013-2020Q1-Q3批签发变化➢人纤维蛋白原批签发已经连续4年下降，2020Q1-Q3人凝血酶原复合物批签发80.1万瓶，同比+20%。单三季度批签发19万瓶，同比-14%，环比-45%。➢2020Q1-Q3有6家企业有批签发，其中上海莱士增长讯速，各企业中，上海莱士39万件、泰邦生物21万件、博雅生物13万件、哈尔滨派斯菲科5万件、绿十字中国3万件卫光生物1万件，分别占比47%、26%、16%、6%、4%和1%。表：2017-2020Q1-Q3各企业批签发量图：2020Q1-Q3各企业批签发量占比-20%0%20%40%60%80%100%020406080100120人纤维蛋白原增速博雅生物16%哈尔滨派斯菲科6%绿十字（中国）4%上海莱士47%泰邦生物26%卫光生物1%标准规格2017201820192020万件Q1Q2Q3合计94.1388.8987.1027.5434.9119.28博雅生物26.1350.7027.333.457.232.23哈尔滨派斯菲科3.851.472.750.60华兰生物7.057.290.24绿十字（中国）6.778.761.052.32上海莱士48.8812.7511.2915.2311.0012.27泰邦生物11.8029.606.3311.613.11天坛生物0.17卫光生物3.201.07中国医药5.136.362.84继续推荐天坛生物、华兰生物、博雅生物，建议关注卫光生物、双林生物15资料来源：中检院及各所，天风证券研究所整理➢头部企业2020Q1-Q3静丙批签发同比大幅提升：⚫天坛生物：静丙批签发同比+7%，狂免同比-15%，破免-52%，白蛋白同比+6%；⚫华兰生物：静丙批签发同比-13%，白蛋白同比+0.5%，破免同比+7%，PCC同比+41%；⚫博雅生物：静丙批签发同比大幅+28%，白蛋白同比+15%，狂免同比+9%，纤原同比-53%；⚫卫光生物：静丙批签发同比+7%，狂免同比+43%，白蛋白同比+34%；⚫双林生物：静丙同比大幅+16%，破免同比+0.3%，白蛋白同比-23%。表：主要上市企业生物批签发量天坛生物2017201820192020Q1-Q3YoY冻干静注人免疫球蛋白（pH4）0.411.93冻干静注乙型肝炎人免疫球蛋白（pH4）1.181.522.542.665%静注人免疫球蛋白（pH4）231.80279.20280.35243.777%狂犬病人免疫球蛋白64.67111.8966.74-15%破伤风人免疫球蛋白67.3249.85138.8750.97-52%人免疫球蛋白43.272.24人凝血酶原复合物0.03人凝血因子Ⅷ0.37人纤维蛋白原0.17人血白蛋白325.23355.41426.24361.606%乙型肝炎人免疫球蛋白17.5815.9527.358.46-39%华兰生物2017201820192020Q1-Q3YoY静注人免疫球蛋白（pH4）153.45110.49139.4889.35-13%狂犬病人免疫球蛋白47.73150.58125.8664.41-34%破伤风人免疫球蛋白125.6186.93140.4585.527%人免疫球蛋白10.8623.8516.516.25-41%人凝血酶原复合物65.3345.3943.0040.2341%人凝血因子Ⅷ51.2164.3062.8642.96-9%人纤维蛋白原7.057.290.24-100%人血白蛋白235.35252.94232.89188.390.5%乙型肝炎人免疫球蛋白39.9728.2312.7919.2350%继续推荐天坛生物、华兰生物、博雅生物，建议关注卫光生物、双林生物16资料来源：中检院及各所，天风证券研究所整理续表：主要上市企业生物批签发量（万件）博雅生物2017201820192020Q1-Q3YoY冻干静注人免疫球蛋白（pH4）1.06-100%静注人免疫球蛋白（pH4）36.5467.9054.2653.0128%狂犬病人免疫球蛋白9.3645.3465.5757.179%人免疫球蛋白8.38人纤维蛋白原26.1350.7027.3312.92-53%人血白蛋白52.1986.2584.4570.7915%乙型肝炎人免疫球蛋白3.67卫光生物2017201820192020Q1-Q3YoY冻干静注人免疫球蛋白（pH4）3.450.77-100%静注人免疫球蛋白（pH4）47.3748.2259.6148.487%狂犬病人免疫球蛋白76.5745.29103.83136.1243%破伤风人免疫球蛋白31.985.3525.944.62-78%人免疫球蛋白18.2712.4724.5113.534%人纤维蛋白原3.201.07人血白蛋白74.2684.4699.4790.8034%乙型肝炎人免疫球蛋白12.0418.606.70双林生物2017201820192020Q1-Q3YoY静注人免疫球蛋白（pH4）33.8134.0449.7147.3416%狂犬病人免疫球蛋白135.3744.49143.4190.30-32%破伤风人免疫球蛋白80.3142.4342.3235.790.3%人免疫球蛋白3.01人血白蛋白85.3184.71109.2964.39-23%乙型肝炎人免疫球蛋白8.4217✓风险提示：1.行业黑天鹅事件；2.新品种研发进展低于预期；3.政策变化风险；4.企业经营质量管理风险风险提示18郑薇：毕业于中国科学技术大学生物化学与分子专业，曾在中科院广州生物医药与健康研究院做过两年课题。毕业后在深圳迈瑞生物医疗电子股份有限公司（美股退市转A股）就职5年。曾在体外诊断事业部做产品研发2年多，后转至战略发展部任职产品市场经理。2015年离开迈瑞，在华泰证券研究所医药团队任高级研究员，负责医疗器械板块；2016年中加入天风证券，2017年入围新财富；2018年任天风证券医药首席分析师。SAC执业证书编号：S1110517110003。潘海洋：南开大学金融学硕士，天津大学生物工程学士。曾就职于华泰证券研究所，任医药生物行业研究员。目前任天风证券医药行业高级分析师，覆盖大药品领域：中药、生物药、部分化药等，善于从政策层面把握行业发展变化趋势，基本面研究扎实，把握公司拐点变化能力强。SAC执业证书编号：S1110517080006。李沙：东北师范大学硕士，哈尔滨工业大学生物工程学士，2018年1月加入天风证券，曾就职于彧辉基金，主要从事大健康、消费、环保等领域投研工作，目前主要负责医药商业板块研究，对药品流通与零售行业较为熟悉。赵楠：中国药科大学药学硕士，沈阳药科大学制药工程学士，南京大学管理学学士，通过CFA一级，2019年3月加入天风证券，曾就职于恒瑞医药，主要从事肿瘤创新药研发，导师为恒瑞全球研发负责人，目前主要研究创新药领域，身处医药行业多年对产业理解较为深入。赵雅韵：西安交通大学化学硕士，制药工程学士，2019年7月加入天风证券，目前主要研究血制品领域。天风医药团队成员简介请务必阅读正文之后的信息披露和免责申明股票投资评级自报告日后的6个月内，相对同期沪深300指数的涨跌幅行业投资评级自报告日后的6个月内，相对同期沪深300指数的涨跌幅买入预期股价相对收益20%以上增持预期股价相对收益10%-20%持有预期股价相对收益-10%-10%卖出预期股价相对收益-10%以下强于大市预期行业指数涨幅5%以上中性预期行业指数涨幅-5%-5%弱于大市预期行业指数涨幅-5%以下投资评级声明类别说明评级体系分析师声明本报告署名分析师在此声明：我们具有中国证券业协会授予的证券投资咨询执业资格或相当的专业胜任能力，本报告所表述的所有观点均准确地反映了我们对标的证券和发行人的个人看法。我们所得报酬的任何部分不曾与，不与，也将不会与本报告中的具体投资建议或观点有直接或间接联系。一般声明除非另有规定，本报告中的所有材料版权均属天风证券股份有限公司（已获中国证监会许可的证券投资咨询业务资格）及其附属机构（以下统称“天风证券”）。未经天风证券事先书面授权，不得以任何方式修改、发送或者复制本报告及其所包含的材料、内容。所有本报告中使用的商标、服务标识及标记均为天风证券的商标、服务标识及标记。本报告是机密的，仅供我们的客户使用，天风证券不因收件人收到本报告而视其为天风证券的客户。本报告中的信息均来源于我们认为可靠的已公开资料，但天风证券对这些信息的准确性及完整性不作任何保证。本报告中的信息、意见等均仅供客户参考，不构成所述证券买卖的出价或征价邀请或要约。该等信息、意见并未考虑到获取本报告人员的具体投资目的、财务状况以及特定需求，在任何时候均不构成对任何人的个人推荐。客户应当对本报告中的信息和意见进行独立评估，并应同时考量各自的投资目的、财务状况和特定需求，必要时就法律、商业、财务、税收等方面咨询专家的意见。对依据或者使用本报告所造成的一切后果，天风证券及/或其关联人员均不承担任何法律责任。本报告所载的意见、评估及预测仅为本报告出具日的观点和判断。该等意见、评估及预测无需通知即可随时更改。过往的表现亦不应作为日后表现的预示和担保。在不同时期，天风证券可能会发出与本报告所载意见、评估及预测不一致的研究报告。天风证券的销售人员、交易人员以及其他专业人士可能会依据不同假设和标准、采用不同的分析方法而口头或书面发表与本报告意见及建议不一致的市场评论和/或交易观点。天风证券没有将此意见及建议向报告所有接收者进行更新的义务。天风证券的资产管理部门、自营部门以及其他投资业务部门可能独立做出与本报告中的意见或建议不一致的投资决策。特别声明在法律许可的情况下，天风证券可能会持有本报告中提及公司所发行的证券并进行交易，也可能为这些公司提供或争取提供投资银行、财务顾问和金融产品等各种金融服务。因此，投资者应当考虑到天风证券及/或其相关人员可能存在影响本报告观点客观性的潜在利益冲突，投资者请勿将本报告视为投资或其他决定的唯一参考依据。19THANKS","data":[{"id":"1","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"白蛋白：2020Q1-Q3批签发约4477万件","content_offset":["1281","1304"],"indicators":[{"indicator_name":"批签发量","indicator_value":["4477万件","1298","1304"],"indicator_element":{"产品":["白蛋白","1281","1284"],"时间":["2020Q1-Q3","1285","1294"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比大幅提升16%","content_offset":["1305","1314"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["16%","1311","1314"],"indicator_element":{"产品":["白蛋白","1281","1284"],"时间":["2020Q1-Q3","1248","1257"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"其中进口白蛋白批签发约2857万件","content_offset":["1315","1332"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2857万件","1326","1332"],"indicator_element":{"产品":["白蛋白","1319","1322"],"渠道":["进口","1317","1319"],"时间":["2020Q1-Q3","1248","1257"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比+约26%","content_offset":["1333","1340"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["26%","1337","1340"],"indicator_element":{"产品":["白蛋白","1281","1284"],"渠道":["进口","1317","1319"],"时间":["2020Q1-Q3","1248","1257"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"批签发占比64%","content_offset":["1341","1349"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["64%","1346","1349"],"indicator_element":{"产品":["白蛋白","1281","1284"],"渠道":["进口","1317","1319"],"时间":["2020Q1-Q3","1248","1257"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"国产白蛋白批签发约1632万件","content_offset":["1350","1365"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1632万件","1359","1365"],"indicator_element":{"产品":["白蛋白","1352","1355"],"渠道":["国产","1350","1352"],"时间":["2020Q1-Q3","1285","1294"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比+约1%","content_offset":["1366","1372"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["1%","1370","1372"],"indicator_element":{"产品":["白蛋白","1281","1284"],"渠道":["国产","1350","1352"],"时间":["2020Q1-Q3","1285","1294"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"批签发占比36%","content_offset":["1373","1381"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["36%","1378","1381"],"indicator_element":{"产品":["白蛋白","1281","1284"],"渠道":["国产","1350","1352"],"时间":["2020Q1-Q3","1285","1294"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"2020Q1-Q3共批签发静丙975.4万瓶","content_offset":["1393","1415"],"indicators":[{"indicator_name":"批签发量","indicator_value":["975.4万瓶","1408","1415"],"indicator_element":{"产品":["静丙","1406","1408"],"时间":["2020Q1-Q3","1393","1402"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比增长+10%","content_offset":["1416","1424"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["10%","1421","1424"],"indicator_element":{"产品":["静丙","1406","1408"],"时间":["2020Q1-Q3","1393","1402"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"狂免近838.1万瓶","content_offset":["1425","1435"],"indicators":[{"indicator_name":"批签发量","indicator_value":["838.1万瓶","1428","1435"],"indicator_element":{"产品":["狂免","1425","1427"],"时间":["2020Q1-Q3","1393","1402"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比-10%","content_offset":["1436","1442"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-10%","1438","1442"],"indicator_element":{"产品":["狂免","1425","1427"],"时间":["2020Q1-Q3","1393","1402"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"破免390.3万瓶","content_offset":["1443","1452"],"indicators":[{"indicator_name":"批签发量","indicator_value":["390.3万瓶","1445","1452"],"indicator_element":{"产品":["破免","1443","1445"],"时间":["2020Q1-Q3","1393","1402"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比-16%","content_offset":["1453","1459"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-16%","1455","1459"],"indicator_element":{"产品":["破免","1443","1445"],"时间":["2020Q1-Q3","1393","1402"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"乙免：2020Q1-Q3批签发约56.1万瓶","content_offset":["1460","1482"],"indicators":[{"indicator_name":"批签发量","indicator_value":["56.1万瓶","1476","1482"],"indicator_element":{"产品":["乙免","1460","1462"],"时间":["2020Q1-Q3","1463","1472"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比-2%","content_offset":["1483","1488"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-2%","1485","1488"],"indicator_element":{"产品":["乙免","1460","1462"],"时间":["2020Q1-Q3","1393","1402"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"因子Ⅷ2020Q1-Q3批签发约166.4万瓶","content_offset":["1494","1517"],"indicators":[{"indicator_name":"批签发量","indicator_value":["166.4万瓶","1510","1517"],"indicator_element":{"产品":["因子Ⅷ","1494","1497"],"时间":["2020Q1-Q3","1497","1506"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比大幅+43%","content_offset":["1518","1526"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["43%","1523","1526"],"indicator_element":{"产品":["因子Ⅷ","1494","1497"],"时间":["2020Q1-Q3","1463","1472"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"PCC批签发约107.4万件","content_offset":["1527","1541"],"indicators":[{"indicator_name":"批签发量","indicator_value":["107.4万件","1534","1541"],"indicator_element":{"产品":["PCC","1527","1530"],"时间":["2020Q1-Q3","1463","1472"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比+41%","content_offset":["664","670"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["41%","667","670"],"indicator_element":{"产品":["PCC","661","664"],"时间":["2020Q1-Q3","1248","1257"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"纤原批签发批签发81.7万件","content_offset":["1549","1563"],"indicators":[{"indicator_name":"批签发量","indicator_value":["81.7万件","1557","1563"],"indicator_element":{"产品":["纤原","1549","1551"],"时间":["2020Q1-Q3","1463","1472"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比+20%","content_offset":["681","687"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["20%","684","687"],"indicator_element":{"产品":["纤原","671","673"],"时间":["2020Q1-Q3","1248","1257"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"单看2020Q3批签发约1316.5万件","content_offset":["2352","2372"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1316.5万件","2364","2372"],"indicator_element":{"产品":["白蛋白","2253","2256"],"时间":["2020Q3","2354","2360"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"环比-15.0%","content_offset":["2373","2381"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["-15.0%","2375","2381"],"indicator_element":{"产品":["白蛋白","2276","2279"],"时间":["2020Q3","2354","2360"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"其中国产576.1万件","content_offset":["2382","2393"],"indicators":[{"indicator_name":"批签发量","indicator_value":["576.1万件","2386","2393"],"indicator_element":{"产品":["白蛋白","2334","2337"],"时间":["2020Q3","2354","2360"],"渠道":["国产","2384","2386"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"环比+12.3%","content_offset":["2394","2402"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["12.3%","2397","2402"],"indicator_element":{"产品":["白蛋白","2334","2337"],"时间":["2020Q3","2354","2360"],"渠道":["国产","2298","2300"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"占比44%","content_offset":["2403","2408"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["44%","2405","2408"],"indicator_element":{"产品":["白蛋白","2334","2337"],"时间":["2020Q3","2354","2360"],"渠道":["国产","2384","2386"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"进口740.4万件","content_offset":["2421","2430"],"indicators":[{"indicator_name":"批签发量","indicator_value":["740.4万件","2423","2430"],"indicator_element":{"产品":["白蛋白","2334","2337"],"时间":["2020Q3","2354","2360"],"渠道":["进口","2421","2423"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"环比-28.5%","content_offset":["2431","2439"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["-28.5%","2433","2439"],"indicator_element":{"产品":["白蛋白","2334","2337"],"时间":["2020Q3","2354","2360"],"渠道":["进口","2332","2334"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"占比56%","content_offset":["2440","2445"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["56%","2442","2445"],"indicator_element":{"产品":["白蛋白","2340","2343"],"时间":["2020Q3","2354","2360"],"渠道":["进口","2421","2423"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"2020Q1-Q3批签发975.4万瓶","content_offset":["3178","3197"],"indicators":[{"indicator_name":"批签发量","indicator_value":["975.4万瓶","3190","3197"],"indicator_element":{"产品":["静注人免疫球蛋白","3093","3101"],"时间":["2020Q1-Q3","3178","3187"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比增幅+10%","content_offset":["3198","3206"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["10%","3203","3206"],"indicator_element":{"产品":["静注人免疫球蛋白","3399","3407"],"时间":["2020Q1-Q3","3124","3133"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"单三季度批签发260.6万瓶","content_offset":["3207","3221"],"indicators":[{"indicator_name":"批签发量","indicator_value":["260.6万瓶","3214","3221"],"indicator_element":{"产品":["静注人免疫球蛋白","3399","3407"],"时间":["单三季度","3207","3211"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比-38%","content_offset":["3222","3228"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-38%","3224","3228"],"indicator_element":{"产品":["静注人免疫球蛋白","3399","3407"],"时间":["单三季度","3207","3211"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"环比+1%","content_offset":["3229","3234"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["1%","3232","3234"],"indicator_element":{"产品":["静注人免疫球蛋白","3399","3407"],"时间":["单三季度","3207","3211"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"2020Q1-Q3狂免批签发近838万瓶","content_offset":["4046","4066"],"indicators":[{"indicator_name":"批签发量","indicator_value":["838万瓶","4061","4066"],"indicator_element":{"产品":["狂免","4055","4057"],"时间":["2020Q1-Q3","4046","4055"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"单三季度批签发256万瓶","content_offset":["4082","4094"],"indicators":[{"indicator_name":"批签发量","indicator_value":["256万瓶","4089","4094"],"indicator_element":{"产品":["狂免","4055","4057"],"时间":["单三季度","4082","4086"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比-42%","content_offset":["4095","4101"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-42%","4097","4101"],"indicator_element":{"产品":["狂免","4055","4057"],"时间":["单三季度","4082","4086"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"环比-22%","content_offset":["4102","4108"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["-22%","4104","4108"],"indicator_element":{"产品":["狂免","4055","4057"],"时间":["单三季度","4082","4086"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"2020Q1-Q3破免批签发390万瓶","content_offset":["4904","4923"],"indicators":[{"indicator_name":"批签发量","indicator_value":["390万瓶","4918","4923"],"indicator_element":{"产品":["破免","4913","4915"],"时间":["2020Q1-Q3","4904","4913"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比-16%","content_offset":["1453","1459"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-16%","1455","1459"],"indicator_element":{"产品":["破免","1443","1445"],"时间":["2020Q1-Q3","1393","1402"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"单三季度批签发85万瓶","content_offset":["4938","4949"],"indicators":[{"indicator_name":"批签发量","indicator_value":["85万瓶","4945","4949"],"indicator_element":{"产品":["破免","4913","4915"],"时间":["单三季度","4938","4942"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比-61%","content_offset":["4950","4956"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-61%","4952","4956"],"indicator_element":{"产品":["破免","4913","4915"],"时间":["单三季度","4938","4942"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"环比-41%","content_offset":["4957","4963"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["-41%","4959","4963"],"indicator_element":{"产品":["破免","4913","4915"],"时间":["单三季度","4938","4942"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"2020Q1-Q3人凝血因子Ⅷ批签发166万瓶","content_offset":["6238","6261"],"indicators":[{"indicator_name":"批签发量","indicator_value":["166万瓶","6256","6261"],"indicator_element":{"产品":["人凝血因子Ⅷ","6247","6253"],"时间":["2020Q1-Q3","6238","6247"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"单三季度批签发65万瓶","content_offset":["6271","6282"],"indicators":[{"indicator_name":"批签发量","indicator_value":["65万瓶","6278","6282"],"indicator_element":{"产品":["人凝血因子Ⅷ","6247","6253"],"时间":["单三季度","6271","6275"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比+37%","content_offset":["6283","6289"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["37%","6286","6289"],"indicator_element":{"产品":["人凝血因子Ⅷ","6247","6253"],"时间":["单三季度","6271","6275"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"环比+59%","content_offset":["6290","6296"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["59%","6293","6296"],"indicator_element":{"产品":["人凝血因子Ⅷ","6247","6253"],"时间":["单三季度","6271","6275"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"2020Q1-Q3人凝血酶原复合物批签发107.4万瓶","content_offset":["6860","6887"],"indicators":[{"indicator_name":"批签发量","indicator_value":["107.4万瓶","6880","6887"],"indicator_element":{"产品":["人凝血酶原复合物","6869","6877"],"时间":["2020Q1-Q3","6860","6869"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"单三季度批签发27万瓶","content_offset":["6895","6906"],"indicators":[{"indicator_name":"批签发量","indicator_value":["27万瓶","6902","6906"],"indicator_element":{"产品":["人凝血酶原复合物","6869","6877"],"时间":["单三季度","6895","6899"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比-28%","content_offset":["6907","6913"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-28%","6909","6913"],"indicator_element":{"产品":["人凝血酶原复合物","6869","6877"],"时间":["单三季度","6895","6899"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"环比-38%","content_offset":["6914","6920"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["-38%","6916","6920"],"indicator_element":{"产品":["人凝血酶原复合物","6869","6877"],"时间":["单三季度","6895","6899"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"单三季度批签发19万瓶","content_offset":["7412","7423"],"indicators":[{"indicator_name":"批签发量","indicator_value":["19万瓶","7419","7423"],"indicator_element":{"产品":["人纤维蛋白原","7360","7366"],"时间":["单三季度","7412","7416"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"同比-14%","content_offset":["7424","7430"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-14%","7426","7430"],"indicator_element":{"产品":["人纤维蛋白原","7360","7366"],"时间":["单三季度","7412","7416"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"2020年Q3血制品批签发报告：整体批签发增长，单季度国产白蛋白占比提升.pdf","content":"环比-45%","content_offset":["7431","7437"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["-45%","7433","7437"],"indicator_element":{"产品":["人纤维蛋白原","7360","7366"],"时间":["单三季度","7412","7416"]},"indicator_supplement":{"属性":""}}]}]}